256 related articles for article (PubMed ID: 14653437)
1. Influence of different anticoagulant agents on fibrinopeptide a generation.
Tobu M; Iqbal O; Messmore HL; Ma Q; Hoppensteadt DA; Fareed J
Clin Appl Thromb Hemost; 2003 Oct; 9(4):273-92. PubMed ID: 14653437
[TBL] [Abstract][Full Text] [Related]
2. Effects of a synthetic factor Xa inhibitor (JTV-803) on various laboratory tests.
Tobu M; Iqbal O; Hoppensteadt DA; Shultz C; Jeske W; Fareed J
Clin Appl Thromb Hemost; 2002 Oct; 8(4):325-36. PubMed ID: 12516682
[TBL] [Abstract][Full Text] [Related]
3. Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): implications for interventional use.
Tobu M; Iqbal O; Ma Q; Schultz C; Jeske W; Hoppensteadt D; Lewis B; Fareed D; Fareed J
Clin Appl Thromb Hemost; 2003 Jan; 9(1):1-17. PubMed ID: 12643318
[TBL] [Abstract][Full Text] [Related]
4. Management of thrombotic and cardiovascular disorders in the new millenium.
Fareed J; Hoppensteadt DA; Bick RL
Clin Appl Thromb Hemost; 2003 Apr; 9(2):101-8. PubMed ID: 12812377
[TBL] [Abstract][Full Text] [Related]
5. Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa.
Siddiqui F; Tafur A; Bontekoe E; Iqbal O; Jeske W; Mehrotra S; Hoppensteadt D; Ramacciotti E; Fareed J
Clin Appl Thromb Hemost; 2020; 26():1076029619895120. PubMed ID: 31914798
[TBL] [Abstract][Full Text] [Related]
6. An update on heparins at the beginning of the new millennium.
Fareed J; Hoppensteadt DA; Bick RL
Semin Thromb Hemost; 2000; 26 Suppl 1():5-21. PubMed ID: 11011802
[TBL] [Abstract][Full Text] [Related]
7. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA
Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
[TBL] [Abstract][Full Text] [Related]
8. Involvement of the extrinsic pathway in the activities of low molecular weight heparins.
Norrheim L; Abildgaard U; Larsen ML; Lindahl AK
Thromb Res Suppl; 1991; 14():19-27. PubMed ID: 1658967
[TBL] [Abstract][Full Text] [Related]
9. Relationship between ex vivo anti-proteinase (factor Xa and thrombin) assays and in vivo anticoagulant effect of very low molecular weight heparin, CY222.
Tew CJ; Lane DA; Thompson E; Ireland H; Curtis JR
Br J Haematol; 1988 Nov; 70(3):335-40. PubMed ID: 2849981
[TBL] [Abstract][Full Text] [Related]
10. Andexanet Alfa Neutralizes the Anticoagulant Effects of Unfractionated Heparin of Bovine, Ovine and Porcine Origin Almost as Protamine Sulfate.
Siddiqui F; Hoppensteadt D; Jeske W; Ramacciotti E; Tafur A; Fareed J
Clin Appl Thromb Hemost; 2024; 30():10760296241247558. PubMed ID: 38656136
[TBL] [Abstract][Full Text] [Related]
11. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.
Graff J; Picard-Willems B; Harder S
Int J Clin Pharmacol Ther; 2007 Apr; 45(4):237-43. PubMed ID: 17474542
[TBL] [Abstract][Full Text] [Related]
12. Laboratory assays for the evaluation of recombinant hirudin.
Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J
Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of unfractionated heparin and low-molecular-weight heparins on tissue thromboplastin inhibition test.
Gerbutavicius R; Iqbal O; Messmore H; Hoppensteadt DA; Demir M; Khan E; Bacher P; Fareed J
Clin Appl Thromb Hemost; 2000 Oct; 6(4):190-6. PubMed ID: 11030523
[TBL] [Abstract][Full Text] [Related]
14. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.
Momi S; Nasimi M; Colucci M; Nenci GG; Gresele P
Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277
[TBL] [Abstract][Full Text] [Related]
15. Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: potential problems in the monitoring of oral anticoagulants.
Tobu M; Iqbal O; Hoppensteadt D; Neville B; Messmore HL; Fareed J
Clin Appl Thromb Hemost; 2004 Oct; 10(4):301-9. PubMed ID: 15497016
[TBL] [Abstract][Full Text] [Related]
16. Heparin monitoring during cardiopulmonary bypass surgery using the one-step point-of-care whole blood anti-factor-Xa clotting assay heptest-POC-Hi.
Hellstern P; Bach J; Simon M; Saggau W
J Extra Corpor Technol; 2007 Jun; 39(2):81-6. PubMed ID: 17672188
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of DX-9065a, argatroban, and synthetic pentasaccharide on tissue thromboplastin inhibition test and dilute Russell's viper venom test.
Gerbutavicius R; Iqbal O; Messmore HL; Wehrmacher WH; Hoppensteadt DA; Gerbutaviciene R; Griniute R; Fareed J
Clin Appl Thromb Hemost; 2003 Oct; 9(4):317-23. PubMed ID: 14653441
[TBL] [Abstract][Full Text] [Related]
18. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation.
Gerotziafas GT; Petropoulou AD; Verdy E; Samama MM; Elalamy I
J Thromb Haemost; 2007 May; 5(5):955-62. PubMed ID: 17461929
[TBL] [Abstract][Full Text] [Related]
19. Activated Clotting Time (ACT) for Monitoring of Low-Dose Heparin: Performance Characteristics in Healthy Adults and Critically Ill Patients.
Wehner JE; Boehne M; David S; Brand K; Tiede A; Bikker R
Clin Appl Thromb Hemost; 2020; 26():1076029620975494. PubMed ID: 33350327
[TBL] [Abstract][Full Text] [Related]
20. Coagulation inhibition capacities of low-molecular mass and unfractionated heparin, as determined by thrombin generation.
Elgue G; Sanchez J; Egberg N; Olsson P
Thromb Res; 1994 Sep; 75(5):539-49. PubMed ID: 7992254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
